Abstract
Cerebrovascular accidents like ischemic stroke and cardiovascular diseases together serve as the cause for 17.7 million deaths, in which Indians account for one-fifth of these cases. Around 4–30% of patients taking clopidogrel have no or reduced antiplatelet response. Clopidogrel response is influenced by genetic factors as well as non-genetic factors such as obesity, hypertension, diabetes mellitus, age, gender, social habits, and drug-drug interactions. This study evaluates the prevalence of P2Y12 and the association between P2Y12 polymorphism and clopidogrel therapy in recurrent stroke and myocardial infarction. A prospective observational study was carried out during November 2024 to June 2025, which included adults above 18 years with the diagnosis of stroke, TIA, MI, on single or dual antiplatelet therapy and excluded pregnant and lactating women as well as history of intracerebral haemorrhage, left ventricular (LV) clot, atrial fibrillation and cardiac embolism. Patients were classified into recurrent and non-recurrent groups based on the presence of recurrent ischemic events. Among the 100 participants who were recruited into the study, 62% of recurrent participants were between the ages of 55–75 years old. Among our cohort participants, the P2Y12 polymorphism showed no significant association with recurrent stroke. The etiological factors, hypertension was significantly associated in recurrent cases (p = 0.029), with longer duration of hypertension leading to recurrence (p = 0.001). Poor glycaemic control (GRBS > 200 mg/dL, 60% recurrent vs. 20% non-recurrent, p = 0.001) and smoking (p = 0.004) were other key risk factors. This study found that the P2Y12 polymorphism was not significantly associated with recurrent events in this study population, while hypertension, poor glycaemic control and smoking demonstrated statistically significant association. Further studies considering large and diverse cohorts with long-term follow-up, incorporating additional polymorphisms in association with recurrent events, may help with a positive outcome. This study emphasises the need to integrate genetic testing into clinical practice could help doctors tailor clopidogrel therapy to individual patients, improving treatment outcomes and reducing recurrent stroke and cardiovascular events.
Data availability
The datasets generated and analysed during the current study include anonymized clinical data and genotyping results related to the P2Y12 G52T polymorphism. Due to institutional ethics and patient confidentiality regulations, individual-level clinical records cannot be made publicly available. However, de-identified datasets supporting the findings of this study are available from the corresponding author upon reasonable request and with approval from the Institutional Ethics Committee.
References
Kambhampati, N. T. et al. Cytochrome P450 2C19 polymorphisms and its association with major adverse cardiac events in post-coronary intervention patients on clopidogrel in the tertiary care center. Cureus [Internet]. 2023 [cited 2025 May 28];15(2):e34737. Available from: https://www.cureus.com/articles/133507-cytochrome-p450-2c19-polymorphisms-and-its-association-with-major-adverse-cardiac-events-in-post-coronary-intervention-patients-on-clopidogrel-in-the-tertiary-care-center
Akkaif, M. A. et al. The role of genetic polymorphism and other factors on clopidogrel resistance (CR) in an Asian population with coronary heart disease (CHD). Molecules 26(7), 1987. https://doi.org/10.3390/molecules26071987 (2021).
Jiang, X.-L., Samant, S., Lesko, L. J. & Schmidt, S. Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin. Pharmacokinet. 54(2), 147–66. https://doi.org/10.1007/s40262-014-0230-6 (2015).
Pradhan, A., Bhandari, M., Vishwakarma, P. & Sethi, R. Clopidogrel resistance and its relevance: Current concepts. J. Family Med. Prim. Care. 13(6), 2187–99. https://doi.org/10.4103/jfmpc.jfmpc_1473_23 (2024).
Lv, J., Chen, A., Xu, C., Shao, G. & Zhao, M. Association of ABCB1 gene polymorphisms with aspirin or clopidogrel resistance in ischemic stroke: a meta-analysis. Int. J. Clin. Exp. Pathol. 18(1), 1–11. https://doi.org/10.62347/IBGQ2413 (2025).
Eskandarian, S., Zafarani, A., Tandel, P., Tamaddon, G. & Amini, A. Evaluation of response to clopidogrel in patients with CYP2C19*2/*3 polymorphisms and its association with miR-19b expression. Mol. Biol. Rep. 52(1), 374. https://doi.org/10.1007/s11033-025-10482-7 (2025).
Wang, L. et al. The role and molecular mechanism of P2Y12 receptors in the pathogenesis of atherosclerotic cardiovascular diseases. Appl. Sci. (Basel) 11(19), 9078. https://doi.org/10.3390/app11199078 (2021).
Danielak, D., Pawlak, K., Główka, F. & Karaźniewicz-Łada, M. Influence of genetic and epigenetic factors of P2Y12 receptor on the safety and efficacy of antiplatelet drugs. Cardiovasc. Drugs Ther. 38(3), 621–36. https://doi.org/10.1007/s10557-022-07370-8 (2024).
Hidayat, R. et al. Correlation P2Y12 genetic polymorphism as risk factor of clopidogrel resistance in Indonesian stroke patients. Vasc. Health Risk Manag. 19, 53–61. https://doi.org/10.2147/VHRM.S386107 (2023).
Kar, R. et al. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms. Platelets 24(4), 297–302. https://doi.org/10.3109/09537104.2012.693992 (2013).
Ahmed, M., Bangash, M. H. & Rafique, M. Polymorphism in the P2Y12 gene & antiplatelet response to clopidogrel in the Pakistani population. Precis. Med. Com. 1(1), 9–16. https://doi.org/10.55627/pmc.001.01.0107 (2021).
Li, Z. et al. Body weight, CYP2C19, and P2Y12 receptor polymorphisms relate to clopidogrel resistance in a cohort of Chinese ischemic stroke patients with aspirin intolerance. Eur. J. Clin. Pharmacol. 76(11), 1517–1527. https://doi.org/10.1007/s00228-020-02946-5 (2020).
Joo, H. J. et al. Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study. Sci. Rep. 8, 1229. https://doi.org/10.1038/s41598-017-18134-y (2018).
Patrono, C. et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 32(23), 2922–2932. https://doi.org/10.1093/eurheartj/ehr373 (2011).
Li, H. et al. Real-time platelet P2Y12 receptor occupancy as a promising pharmacodynamics biomarker for bridging the gap between PK/PD of clopidogrel therapy. Acta Pharm Sin B 15(1), 484–493. https://doi.org/10.1016/j.apsb.2024.08.008 (2025).
Ta Anh, H. et al. Association of P2RY12 gene variants and non-genetic factors with clopidogrel responsiveness in Vietnamese patients after percutaneous coronary intervention: A cross-sectional study. J. Clin. Lab. Anal. 39(5), e70003. https://doi.org/10.1002/jcla.70003 (2025).
Zhang, Y. J. et al. Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease. BMC Cardiovasc. Dis. 22(1), 575. https://doi.org/10.1186/s12872-022-02988-w (2022).
Wadowski, P. P. et al. Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors. Res. Pract. Thromb. Haemost. 3(3), 383–390. https://doi.org/10.1002/rth2.12213 (2019).
Sukumaran, B. et al. Prevalence of CYP2C19 Poor Metabolisers Among South Indian Psychiatric Patients: A Pharmacogenetic Perspective Toward Precision Psychopharmacology. Annals Neurosci. https://doi.org/10.1177/09727531251379157 (2025).
Chen, C., Reeves, M. J., He, K., Morgenstern, L. B. & Lisabeth, L. D. Sex differences in trends in stroke recurrence and postrecurrence mortality 2000–2020: Population-based Brain Attack Surveillance in Corpus Christi project. Ann. Neurol. 96(2), 332–342. https://doi.org/10.1002/ana.26955 (2024).
Mbalinda, S. N. et al. Stroke recurrence rate and risk factors among stroke survivors in sub-Saharan Africa: A systematic review. Neuropsychiatr. Dis. Treat 20, 783–791. https://doi.org/10.2147/NDT.S442507 (2024).
Chiangkhong, A., Suwanwong, C. & Wongrostrai, Y. Lifestyle, clinical, and occupational risk factors of recurrent stroke among the working-age group: A systematic review and meta-analysis. Heliyon 9(3), e13949. https://doi.org/10.1016/j.heliyon.2023.e13949 (2023).
Chen, J. et al. Impact of smoking status on stroke recurrence. J. Am. Heart Assoc. 8(8), e011696. https://doi.org/10.1161/JAHA.118.011696 (2019).
Zhang, Y. et al. Association between diabetes duration and 1-year prognosis of stroke: A national registry study. Brain Behav. 12(9), e2725. https://doi.org/10.1002/brb3.2725 (2022).
Funding
Open access funding provided by Amrita Vishwa Vidyapeetham. All the expenses were borne from the Institutional project fund.
Author information
Authors and Affiliations
Contributions
U.K., V. N., M.K., and AB.C., jointly conceived theidea and set up the model; A.B., and R.M. performed the calculations andcomposed the first draft of the manuscript; S.D., C.R, and C. S. refined themodel, K.T., provided helpful discussions; R.P., G.T., R.R., K.K., and S.H.coordinated the work. All authors have contributed to writing the manuscript.All authors have read and agreed to the published version of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Dual publication
We declare that this manuscript is not a duplicate or overlapping publication. The ABCB1 and P2Y12 studies were conducted independently with different cohorts and are submitted as separate manuscripts. Neither manuscript is dependent on the acceptance of the other.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Baiju, A., Riyas, M., Rajalakshmi, S. et al. Association of P2Y12 G52T genetic polymorphism with recurrent thromboembolic events in stroke and myocardial infarction patients on clopidogrel therapy: a prospective observational study. Sci Rep (2026). https://doi.org/10.1038/s41598-026-44969-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-44969-5
